Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis drug shows promise in chinese trial

NCT ID NCT06011733

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve clear or almost clear skin (IGA 0/1) compared to placebo. The trial is completed, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bimekizumab
What this could lead to
If successful, bimekizumab could offer a new treatment option for Chinese adults with moderate to severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong
This is a phase 3 trial, but results are not yet published. As with any drug, side effects are possible, and it may not work for everyone. Long-term safety and effectiveness are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

133 people

The number who actually took part.

Started

Oct 2023

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Study participant is Chinese male or female ≥18 years of age * Study participant has plaque psoriasis (PSO) for ≥6 months prior to the Screening Visit * Study participant has Psoriasis Area and Severity Index (PASI) ≥12 and body surface area (BSA) affected by PSO ≥10% and Investigator's Global Assessment (IGA) score ≥3 on a 5-point scale. * Study participant is a candidate for systemic PSO therapy and/or phototherapy * Female study participants must be postmenopausal or permanently sterilized or if childbearing potential must be willing to use protocol defined highly effective method of contraception throughout the duration of the study until 17 weeks after last administration of investigational medicinal product (IMP) and have a negative pregnancy test at Screening and prior to first dose Exclusion Criteria: * Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 17 weeks following the final dose of IMP * Study participant has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic, guttate, or drug-induced PSO) * Study participant has an active infection or history of infection(s) as defined in the protocol * Study participant has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection.Study participant has a past history of active TB involving any organ system unless adequately treated and is proven to be fully recovered upon consult with a TB specialist * Study participant has a diagnosis of inflammatory conditions other than PSO vulgaris or psoriatic arthritis (PsA) * Study participant has presence of significant uncontrolled neuropsychiatric disorder. Study participants with history of suicide attempt within the 5 years prior to the Screening Visit must be excluded. Study participants with history of suicide attempt more than 5 years prior to the Screening Visit must be evaluated by a mental health care practitioner before enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic plaque psoriasis Moderate-to-severe chronic plaque psoriasis

Contacts and locations

Locations

  • Ps0041 20022

    Hangzhou, China

  • Ps0041 20023

    Beijing, China

  • Ps0041 20117

    Guangzhou, China

  • Ps0041 20120

    Wuhan, China

  • Ps0041 20136

    Tianjin, China

  • Ps0041 20184

    Shenzhen, China

  • Ps0041 20193

    Hangzhou, China

  • Ps0041 20247

    Beijing, China

  • Ps0041 20296

    Hangzhou, China

  • Ps0041 20306

    Beijing, China

  • Ps0041 20308

    Shanghai, China

  • Ps0041 20309

    Xi'an, China

  • Ps0041 20310

    Ningbo, China

  • Ps0041 20311

    Guangzhou, China

  • Ps0041 20312

    Jinan, China

  • Ps0041 20313

    Guangzhou, China

  • Ps0041 20314

    Wuxi, China

  • Ps0041 20318

    Jinan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.